$DXCM
DEXCOM INC Stock $dxcm

$dxcm Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000109355716000511 Filed on April 27, 2016

Income Statement

Concept	2016 Q1	2015 Q1
Revenue	$116.2M	$72.80M
YoY Change	59.62%	54.56%
Cost Of Revenue	$41.10M	$26.30M
YoY Change	56.27%	52.02%
Gross Profit	$75.10M	$46.50M
YoY Change	61.51%	56.04%
Gross Profit Margin	64.63%	63.87%
Selling, General & Admin	$62.10M	$39.40M
YoY Change	57.61%	42.75%
% of Gross Profit	82.69%	84.73%
Research & Development	$32.20M	$19.80M
YoY Change	62.63%	36.55%
% of Gross Profit	42.88%	42.58%
Depreciation & Amortization	$3.400M	$2.400M
YoY Change	41.67%	26.32%
% of Gross Profit	4.53%	5.16%
Operating Expenses	$94.30M	$59.20M
YoY Change	59.29%	40.62%
Operating Profit	-$19.20M	-$12.70M
YoY Change	51.18%	3.25%
Interest Expense	$100.0K	$200.0K
YoY Change	-50.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	$0.00
YoY Change
Pretax Income	-$19.20M	-$12.90M
YoY Change	48.84%	3.2%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$19.20M	-$12.90M
YoY Change	48.84%	3.2%
Net Earnings / Revenue	-16.52%	-17.72%
Basic Earnings Per Share
Diluted Earnings Per Share	-$233.9K	-$165.8K
COMMON SHARES
Basic Shares Outstanding	82.10M shares	77.80M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$106.5M	$83.80M
YoY Change	27.09%	45.99%
Cash & Equivalents	$77.90M	$54.20M
Short-Term Investments	$28.60M	$29.60M
Other Short-Term Assets	$7.500M	$3.800M
YoY Change	97.37%	8.57%
Inventory	$46.10M	$18.40M
Prepaid Expenses
Receivables	$67.30M	$40.20M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$227.4M	$146.2M
YoY Change	55.54%	56.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$65.90M	$35.70M
YoY Change	84.59%	55.9%
Goodwill	$3.700M	$3.200M
YoY Change	15.63%	0.0%
Intangibles	$2.000M	$2.600M
YoY Change	-23.08%	-23.53%
Long-Term Investments
YoY Change
Other Assets	$400.0K	$600.0K
YoY Change	-33.33%	-25.0%
Total Long-Term Assets	$72.00M	$43.10M
YoY Change	67.05%	37.7%
TOTAL ASSETS
Total Short-Term Assets	$227.4M	$146.2M
Total Long-Term Assets	$72.00M	$43.10M
Total Assets	$299.4M	$189.3M
YoY Change	58.16%	51.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.50M	$10.90M
YoY Change	97.25%	127.08%
Accrued Expenses	$40.30M	$22.40M
YoY Change	79.91%	1.36%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.700M	$2.400M
YoY Change	-29.17%	9.09%
Total Short-Term Liabilities	$64.10M	$37.00M
YoY Change	73.24%	24.58%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$1.700M
YoY Change	-100.0%	-58.54%
Other Long-Term Liabilities	$4.100M	$2.000M
YoY Change	105.0%	81.82%
Total Long-Term Liabilities	$4.100M	$2.000M
YoY Change	105.0%	81.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$64.10M	$37.00M
Total Long-Term Liabilities	$4.100M	$2.000M
Total Liabilities	$68.20M	$40.70M
YoY Change	67.57%	16.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$574.6M	-$510.7M
YoY Change	12.51%	4.67%
Common Stock	$806.0M	$659.5M
YoY Change	22.21%	14.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$231.2M	$148.6M
YoY Change
Total Liabilities & Shareholders Equity	$299.4M	$189.3M
YoY Change	58.16%	51.56%

Cashflow Statement

Concept	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$19.20M	-$12.90M
YoY Change	48.84%	3.2%
Depreciation, Depletion And Amortization	$3.400M	$2.400M
YoY Change	41.67%	26.32%
Cash From Operating Activities	-$200.0K	$3.400M
YoY Change	-105.88%	-241.67%
INVESTING ACTIVITIES
Capital Expenditures	$11.50M	$8.000M
YoY Change	43.75%	105.13%
Acquisitions
YoY Change
Other Investing Activities	$300.0K	-$17.90M
YoY Change	-101.68%	4375.0%
Cash From Investing Activities	-$11.20M	-$25.90M
YoY Change	-56.76%	502.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$3.800M	$5.500M
YoY Change	-30.91%	-43.3%
Debt Paid & Issued, Net	$600.0K	$600.0K
YoY Change	0.0%	20.0%
Cash From Financing Activities	$3.200M	$4.900M
YoY Change	-34.69%	-46.74%
NET CHANGE
Cash From Operating Activities	-$200.0K	$3.400M
Cash From Investing Activities	-$11.20M	-$25.90M
Cash From Financing Activities	$3.200M	$4.900M
Net Change In Cash	-$8.200M	-$17.60M
YoY Change	-53.41%	-804.0%
FREE CASH FLOW
Cash From Operating Activities	-$200.0K	$3.400M
Capital Expenditures	$11.50M	$8.000M
Free Cash Flow	-$11.70M	-$4.600M
YoY Change	154.35%	-26.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001093557
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83431929	shares
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	DEXCOM INC
CY2016Q1	dei	Trading Symbol TradingSymbol	DXCM
CY2015Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	2100000	USD
CY2016Q1	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	2900000	USD
CY2015Q4	dxcm	Clinical Trials ClinicalTrials	700000	USD
CY2016Q1	dxcm	Clinical Trials ClinicalTrials	400000	USD
CY2012Q4	dxcm	Debt Instrument Basis Spread On Treasury Variable Rate DebtInstrumentBasisSpreadOnTreasuryVariableRate	0.0694
CY2016Q1	dxcm	Potential Rental Rate Adjustment Maximum PotentialRentalRateAdjustmentMaximum	0.04
CY2016Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	106500000	USD
CY2015Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	32100000	USD
CY2016Q1	dxcm	Potential Rental Rate Adjustment Minimum PotentialRentalRateAdjustmentMinimum	0.025
CY2016Q1	dxcm	Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm	P1Y
CY2016Q1	dxcm	Sales Return Coverage Period SalesReturnCoveragePeriod	P30D
CY2012Q4	dxcm	Term Loan Advances Aggregate Amount TermLoanAdvancesAggregateAmount	7000000	USD
CY2012Q4	dxcm	Term Loan Debt TermLoanDebt	20000000	USD
CY2016Q1	dxcm	Working Capital WorkingCapital	163300000	USD
CY2015Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	38900000	USD
CY2016Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	45100000	USD
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	19000000	USD
CY2016Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	21500000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	74100000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	67300000	USD
CY2015Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-100000	USD
CY2016Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-100000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-300000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-300000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	776800000	USD
CY2016Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	806000000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	100000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7100000	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5100000	shares
CY2015Q4	us-gaap	Assets Assets	292000000	USD
CY2016Q1	us-gaap	Assets Assets	299400000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	231300000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	227400000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	29100000	USD
CY2016Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	28600000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2016Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	29100000	USD
CY2016Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	28600000	USD
CY2016Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	24800000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	29100000	USD
CY2016Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	28600000	USD
CY2016Q1	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	3800000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71800000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54200000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86100000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77900000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-17600000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8200000	USD
CY2016Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	32600000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82000000	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83700000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81700000	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83400000	shares
CY2015Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2016Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13100000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19200000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	26300000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	41100000	USD
CY2012Q4	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	13000000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	800000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	600000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2400000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3400000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	24900000	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16700000	USD
CY2016Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	216600000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	3700000	USD
CY2016Q1	us-gaap	Goodwill Goodwill	3700000	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	46500000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	75100000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.17
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.23
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1600000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3700000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2200000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6800000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	600000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-200000	USD
CY2015Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-5100000	USD
CY2016Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-8200000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2400000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10900000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	500000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	200000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-200000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1000000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2200000	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2000000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	200000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	100000	USD
CY2015Q1	us-gaap	Interest Income Other InterestIncomeOther	0	USD
CY2016Q1	us-gaap	Interest Income Other InterestIncomeOther	100000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	16600000	USD
CY2016Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	19800000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	35200000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	46100000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	16000000	USD
CY2016Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	23400000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2600000	USD
CY2016Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2900000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	70800000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	68200000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	292000000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	299400000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	66900000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	64100000	USD
CY2012Q4	us-gaap	Line Of Credit LineOfCredit	15000000	USD
CY2016Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1700000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4900000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3200000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25900000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11200000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3400000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-200000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-12900000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-19200000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	59200000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	94300000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12700000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19200000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	49700000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	4300000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	9500000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	9000000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	8100000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	6500000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	12300000	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1900000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17100000	USD
CY2016Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20300000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	100000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	400000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2016Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2015Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-200000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3900000	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4100000	USD
CY2015Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	200000	USD
CY2016Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2015Q3	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-1800000	USD
CY2012	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1100000	USD
CY2015Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	22600000	USD
CY2016Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	10800000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8000000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11500000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2016Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6800000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7500000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5500000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3800000	USD
CY2015Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	4700000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	11100000	USD
CY2015Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1400000	USD
CY2016Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	3800000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	54700000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65900000	USD
CY2016Q1	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	58400000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	600000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	600000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19800000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32200000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-555400000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-574600000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	72800000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	116200000	USD
CY2015Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	2300000	USD
CY2016Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	1700000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	39400000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	62100000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	15900000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	25100000	USD
CY2014Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1300000	USD
CY2015Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1100000	USD
CY2015Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	3300000	USD
CY2016Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	5700000	USD
CY2015Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	1200000	USD
CY2016Q1	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	6200000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	221200000	USD
CY2016Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	231200000	USD
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77800000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82100000	shares
CY2016Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DexCom, Inc. is a medical device company focused on the design, development and commercialization of</font><font style="font-family:inherit;font-size:10pt;"> continuous glucose monitoring (“CGM”)</font><font style="font-family:inherit;font-size:10pt;"> systems for ambulatory use by people with diabetes and by healthcare providers in the hospital for the treatment of people with and without diabetes. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to DexCom, Inc. and its subsidiaries.</font></div></div>
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with </font><font style="font-family:inherit;font-size:10pt;">U.S. GAAP</font><font style="font-family:inherit;font-size:10pt;"> requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, valuation of inventory, warranty accruals, employee bonus, clinical trial expenses, allowance for bad debt, refunds and rebates, including pharmacy rebates and share-based compensation expense. </font></div></div>

Files In Submission

Name	View Source	Status
0001093557-16-000511-index-headers.html	Edgar Link	pending
0001093557-16-000511-index.html	Edgar Link	pending
0001093557-16-000511.txt	Edgar Link	pending
0001093557-16-000511-xbrl.zip	Edgar Link	pending
a32ndamendmententropi_image1.jpg	Edgar Link	pending
dxcm-03312016x10q.htm	Edgar Link	pending
dxcm-20160331.xml	Edgar Link	completed
dxcm-20160331.xsd	Edgar Link	pending
dxcm-20160331_cal.xml	Edgar Link	unprocessable
dxcm-20160331_def.xml	Edgar Link	unprocessable
dxcm-20160331_lab.xml	Edgar Link	unprocessable
dxcm-20160331_pre.xml	Edgar Link	unprocessable
dxcm03312016ex1036.htm	Edgar Link	pending
dxcm03312016ex1037.htm	Edgar Link	pending
dxcm03312016ex3101.htm	Edgar Link	pending
dxcm03312016ex3102.htm	Edgar Link	pending
dxcm03312016ex3201.htm	Edgar Link	pending
dxcm03312065ex3202.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DXCM
DEXCOM INC Stock $dxcm

2016 Q1 Form 10-Q Financial Statement

#000109355716000511 Filed on April 27, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM DEXCOM INC Stock $dxcm

2016 Q1 Form 10-Q Financial Statement

#000109355716000511 Filed on April 27, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM
DEXCOM INC Stock $dxcm